EMSCs and PMSCs treatments effectively reduce the expression of pro-inflammatory factors IFN-γ *P < 0.01Vs Normal group (3w Vehicle group: F = 3.41, P < 0.0001;EMSCs group: F = 6.24, P < 0.0001, PMECs group: F = 0.18, P = 0.0053; 8w PI, Vehicle group: F = 0.23, P < 0.0001;EMSCs group: F = 0.74, P < 0.0001; PMECs group: F = 0.73, P = 0.0031) & P < 0.01 Vs Vehicle group (3w PI, EMSCs group: F = 0.54, P < 0.0001; PMECs group: F = 0.62, P < 0.0001. 8w PI, EMSCs group: F = 3.12, P < 0.0001; PMECs group: F = 0.13, P < 0.0001). #P < 0.01 Vs EMSCs group (3w PI, PMSCs group: F = 1.14, P < 0.0001; 8w PI, PMSCs group: F = 0.43, P < 0.0001) (A,B) and IL-2 *P < 0.01Vs Normal group (3w Vehicle group: F = 0.22, P < 0.0001; 8w PI, Vehicle group: F = 0.6, P < 0.0001) & P < 0.01 Vs Vehicle group (3w PI, EMSCs group: F = 2.51, P < 0.0001; PMECs group: F = 0.8, P < 0.0001. 8w PI, EMSCs group: F = 0.4, P < 0.0001; PMECs group: F = 0.45, P < 0.0001) (C,D), but up regulated the expression of anti-inflammatory cytokines TGF-β *P < 0.01Vs Normal group (3w Vehicle group: F = 0.1, P < 0.0001;EMSCs group: F = 0.06, P < 0.0001. PMECs group: F = 0.043, P < 0.0001; 8w PI, Vehicle group: F = 0.39, P < 0.0001.EMSCs group: F = 0.11, P < 0.0001. PMECs group: F = 0.15, P < 0.0001).& P < 0.01 Vs Vehicle group (3w PI, EMSCs group: F = 0.58, P = 0.00013; PMECs group: F = 0.42, P < 0.0001. 8w PI, EMSCs group: F = 0.28, P < 0.0001; PMECs group: F = 0.4, P < 0.0001). (E,F) and IL-4 *P < 0.01Vs Normal group (3w Vehicle group: F = 0.14, P = 0.017; EMSCs group: F = 0.39, P < 0.0001, PMECs group: F = 0.46, P < 0.0001; 8w PI, Vehicle group: F = 0.0038, P < 0.0001; EMSCs group: F = 0.0017, P < 0.0001; PMECs group: F = 0.00167, P < 0.0001). &P < 0.01 Vs Vehicle group (3w PI, EMSCs group: F = 1.25, P < 0.0001; PMECs group: F = 1.45, P < 0.0001. 8w PI, EMSCs group: F = 0.45, P < 0.0001; PMECs group: F = 0.44, P < 0.0001). #P < 0.01 Vs EMSCs group (3w PI, PMSCs group: F = 0.86, P = 0.00017). Data are represented as mean ± SD. n = 5, degrees of freedom = 4.